Kathy S. Albain
- Oncology top 0.05%
- Cancer Treatment and Pharmacology 47
- HER2/EGFR in Cancer Research 43
- Lung Cancer Research Studies 43
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations 66
- Lung Cancer Diagnosis and Treatment 39
- Advanced Breast Cancer Therapies 29
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies 63
- Otorhinolaryngology top 0.5%
-
- Estrogen and related hormone effects 19
- Co-authors
- John J. CrowleyRobert B. LivingstonJoseph M. UngerCharles A. ColtmanLaura F. HutchinsDavid R. GandaraMichael LeBlancKaren Kelly
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Kathy S. Albain
229 papers receiving 18.5k citations
Hit Papers
Peers
Comparison fields: 5 of 151
- Oncology 11.9k
- Pulmonary and Respiratory Medicine 9.2k
- Cancer Research 3.8k
- Otorhinolaryngology 456
- Radiology, Nuclear Medicine and Imaging 2.1k
Countries citing papers authored by Kathy S. Albain
This map shows the geographic impact of Kathy S. Albain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathy S. Albain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathy S. Albain more than expected).
Fields of papers citing papers by Kathy S. Albain
This network shows the impact of papers produced by Kathy S. Albain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathy S. Albain. The network helps show where Kathy S. Albain may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kathy S. Albain, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 16 | |
| 2 | 2024 | 10 | |
| 3 | 2024 | 5 | |
| 4 | 2024 | 1 | |
| 5 | 2023 | 15 | |
| 6 | 2023 | 9 | |
| 7 | 2021 | 1 | |
| 8 | 2019 | 32 | |
| 9 | 2017 | 158 | |
| 10 | 2013 | 148 | |
| 11 | 2013 | 145 | |
| 12 | 2011 | 45 | |
| 13 | 2011 | 110 | |
| 14 | Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. | 2010 | 119 |
| 15 | 2010 | 3 | |
| 16 | 2009 | 64 | |
| 17 | 2008 | 421 | |
| 18 | 2006 | 5 | |
| 19 | Double blind phase III trial of placebo (P) vs. megestrol acetate (MA) 20 mg vs. MA 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: Initial results of Southwest Oncology Group S9626 | 2001 | 2 |
| 20 | Age less than 35 is associated with high percent S-phase, abnormal P53, and adverse breast cancer outcome | 1993 | 9 |
About Kathy S. Albain
Kathy S. Albain is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 234 papers that have together received 19.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (66 papers), Breast Cancer Treatment Studies (63 papers), Cancer Treatment and Pharmacology (47 papers), HER2/EGFR in Cancer Research (43 papers), Lung Cancer Research Studies (43 papers), Lung Cancer Diagnosis and Treatment (39 papers), Advanced Breast Cancer Therapies (29 papers) and Estrogen and related hormone effects (19 papers). The work is most often cited by research in Oncology (11.9k citations), Pulmonary and Respiratory Medicine (9.2k citations) and Cancer Research (3.8k citations). Kathy S. Albain has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include John J. Crowley, Robert B. Livingston, Joseph M. Unger, Charles A. Coltman, Laura F. Hutchins, David R. Gandara, Michael LeBlanc, Karen Kelly, Valerie W. Rusch and Andrew T. Turrisi. Their work appears in journals such as New England Journal of Medicine, The Lancet and JAMA.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.